Phase III PEMPHIX Study of Roche’s Rituxan (rituximab) shows positive results
Roche has unveiled positive results from the Phase III PEMPHIX study of MabThera/Rituxan (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris (PV).